Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Tenza Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, which suggests that the company's research spans different specialized fields within the life sciences. The involvement of multiple distinct examiners indicates that each pending matter is being reviewed independently by a different official. This distribution requires the applicant to maintain a flexible prosecution strategy that can adapt to the specific requirements of multiple examining groups.
The busiest examiner, GROOMS, TIFFANY NICOLE, is responsible for 1 pending office action. Given the total of 2 pending office actions, the workload is divided between the examiners. This distribution means that Tenza Inc. must navigate different sets of examiner expectations and multiple art unit cultures simultaneously. Practitioners should be prepared for varied feedback, as the assigned officials may prioritize different aspects of patentability within the Biotechnology & Pharmaceuticals sector.
The presence of 2 distinct art units may require the applicant to employ different technical arguments for each case. Because there is no single point of contact for the portfolio's active matters, the strategy for responding to office actions must be tailored to the specific preferences of each individual. This level of examiner diversity provides multiple opportunities for the applicant to secure patent protection through different channels. Successfully navigating these distinct art units will be essential for the continued growth of the portfolio in the life sciences field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GROOMS, TIFFANY NICOLE | 1 | 57.8% | +46.3% |
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904038 | BIO-THERAPEUTICS FOR DETECTION, DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH MUCOSAL BLEEDING | JOHANSEN, PETER N. | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17904038 | BIO-THERAPEUTICS FOR DETECTION, DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH MUCOSAL BLEEDING | JOHANSEN, PETER N. | 21d |
| 18281388 | SYNTHETIC PRE-PROTEIN SIGNAL PEPTIDES FOR DIRECTING SECRETION OF HETEROLOGOUS PROTEINS IN BACILLUS BACTERIA | GROOMS, TIFFANY NICOLE | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18281388 | SYNTHETIC PRE-PROTEIN SIGNAL PEPTIDES FOR DIRECTING SECRETION OF HETEROLOGOUS PROTEINS IN BACILLUS BACTERIA | GROOMS, TIFFANY NICOLE | 1658 | §112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 17904038 | BIO-THERAPEUTICS FOR DETECTION, DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH MUCOSAL BLEEDING | JOHANSEN, PETER N. | 1644 | §102§103§112 | Non-Final OA | 21d | Pending | Aug 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial